intravenous immunoglobulin (IVIG) / Guys and St Thomas NHS Foundation Trust 
Welcome,         Profile    Billing    Logout  
 14 Diseases   1 Trial   1 Trial   12 News 
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
    Efficacy of rituximab in the treatment of epidermolysis bullosa acquisita (e-Poster Hall) -  Aug 8, 2023 - Abstract #EADV2023EADV_1841;    
    Conclusion Rituximab was well tolerated and resulted in clinical improvement in 71% of our patient cohort and enabled dose reduction of prednisolone and other immunomodulatory therapies in the majority of patients. This study represents the largest reported cohort of EBA patients treated with rituximab and supports it
  • ||||||||||  intravenous immunoglobulin (IVIG) / Guy's and St Thomas' NHS Foundation Trust, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Clinical, Retrospective data, Journal:  Clinical features, investigations, and outcomes of pediatric limbic encephalitis: A multicenter study. (Pubmed Central) -  Mar 17, 2022   
    They summarize evidence- and expert-based recommendations useful in clinical practice. A diagnosis of autoimmune LE was associated with significant morbidity and adverse outcomes in this pediatric cohort.
  • ||||||||||  intravenous immunoglobulin (IVIG) / Guy's and St Thomas' NHS Foundation Trust, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Retrospective data, Journal:  Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis: A Meta-analysis. (Pubmed Central) -  Jan 15, 2022   
    Factors at first event that were significantly associated with good functional outcome included adolescent age and first-line treatment with therapeutic apheresis, corticosteroids plus intravenous immunoglobulin (IVIG), or corticosteroids plus IVIG plus therapeutic apheresis...Factors significantly associated with nonrelapsing disease were rituximab use or maintenance IVIG use for 6 months or more...Modified NEOS score (including 4 of 5 original NEOS items) was associated with probability of poor functional status at 1 year (20.1% [40 of 199] for a score of 0 to 1 points; 43.8% [77 of 176] for a score of 3 to 4 points; P = .05). Factors influencing functional outcomes and relapse are different and need to be considered independently in development of evidence-based optimal management guidelines of patients with NMDARE.
  • ||||||||||  [VIRTUAL] Toxic epidermal necrolysis in the setting of systemic lupus erythematosus: a case series () -  Jul 5, 2021 - Abstract #BAD2021BAD_577;    
    She was found to have a high antinuclear antibody, double-stranded DNA and low complement, was diagnosed with SLE and treated with steroids, lansoprazole and hydroxychloroquine, and developed a widespread bullous eruption...The culprit drugs were thought to be clarithromycin or omeprazole...In the third patient only, immunofluorescence was consistent with lupus. These patients had a protracted ITU stay of 18, 43 and 16 days, respectively, vs. an average stay of 12 days in our hospital for patients with TEN.